Maryland-primarily based biotechnology organization Emergent BioSolutions on Monday said it had obtained a $1.25 billion deal to supply the U.S. government with forty four.75 million doses of an anthrax vaccine (see GSN, June 1).
BioThrax is the only anthrax vaccine accredited by the U.S. Food and Drug Administration.
"Emergent is happy to be capable to contribute to the U.S. government's program of defending the nation from the threat of anthrax," business Chief Executive Officer and Chairman Fuad El-Hibri stated in presented comments. "This 5-year award offers for uninterrupted supply of this crucial biodefense countermeasure although addressing the government's mandate to lessen investing across all applications."
Delivery of the first 8.5 million doses is predicted inside the following year. Completion of the contract is scheduled for September 2016, presuming funding carries on. The company also has the appropriate to alter the delivery timetable based on production ranges and other variables (Emergent BioSolutions release, Oct. 3) ( via gsn.nti.org ).